Electroconvulsive Therapy for Neuropsychiatric Symptoms due to Major Neurocognitive Disorder: A Prospective, Observational Study.
Journal
The journal of ECT
ISSN: 1533-4112
Titre abrégé: J ECT
Pays: United States
ID NLM: 9808943
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
entrez:
25
5
2022
pubmed:
26
5
2022
medline:
28
5
2022
Statut:
ppublish
Résumé
Neuropsychiatric symptoms (NPSs) in those with major neurocognitive disorder (MNCD) include the responsive behaviors of agitation and aggression. Electroconvulsive therapy (ECT) has shown some effectiveness based on retrospective studies and one open label prospective study. We hypothesized that ECT will reduce NPSs between baseline and after treatment in those with medication-refractory behaviors. This Canadian prospective multicenter study included MNCD patients admitted to geriatric psychiatry units for the management of refractory NPSs. All treatment-refractory participants suffered from advanced MNCD. We conducted the Neuropsychiatric Inventory-Clinician version and the Pittsburgh Agitation Scale at baseline, and during and after the ECT course. A bitemporal or bifrontal ECT series based on dose titration to 1.5 to 2.5 times seizure threshold was administered. Data were collected for 33 patients with a mean age of 73 and categorized with severe MNCD using the Functional Assessment Staging of Alzheimer's Disease scale (stages 6 and 7). The data showed a drop in mean Neuropsychiatric Inventory-Clinician version from 58.36 to 24.58 (P < 0.0001). Mean Neuropsychiatric Inventory agitation subscale dropped from 7.12 to 3.09 (P = 0.007). Mean Neuropsychiatric Inventory aggression subscale dropped from 6.94 to 0.97 (P < 0.0001). There was a concomitant significant decline in Pittsburgh Agitation Scale scores. No participants dropped out because of intolerance of ECT. One participant died from pneumonia, which did not appear related to ECT. In this naturalistic study, ECT was found to be a safe and effective treatment for certain NPSs in people with MNCD. This can translate into improving quality of life.
Identifiants
pubmed: 35613007
doi: 10.1097/YCT.0000000000000814
pii: 00124509-202206000-00005
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-87Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
P.C. is a coowner of Brainstim (rTMS) Healthcare, advisory board for Janssen-Ortho. The remaining authors have no conflicts of interest or financial disclosures to report.
Références
American Psychiatric Association. DSM-5 Task Force: Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 5th . Washington, DC: American Psychiatric Association; 2013.
WHO: World Health Organization Website: Factsheet on Dementia. 2019.
Norton LE, Malloy PF, Salloway S. The impact of behavioral symptoms on activities of daily living in patients with dementia. Am J Geriatr Psychiatry . 2001;9:41–48.
Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA . 2002;288:1475–1483.
Matsumoto N, Ikeda M, Fukuhara R, et al. Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord . 2007;23:219–224.
Okura T, Langa KM. Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Dis Assoc Disord . 2011;25:116–121.
Aigbogun MS, Stellhorn R, Hartry A, et al. Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis. BMC Neurol . 2019;19:33.
Azermai M, Petrovic M, Elseviers MM, et al. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res Rev . 2012;11:78–86.
Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry . 2014;205:436–442.
Maust DT, Langa KM, Blow FC, et al. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. Int J Geriatr Psychiatry . 2017;32:164–174.
Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry . 2012;169:71–79.
Aupperle P. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am J Alzheimers Dis Other Demen . 2006;21:101–108.
Geduldig ET, Kellner CH. Electroconvulsive therapy in the elderly: new findings in geriatric depression. Curr Psychiatry Rep . 2016;18:40.
Oudman E. Is electroconvulsive therapy (ECT) effective and safe for treatment of depression in dementia? A short review. J ECT . 2012;28:34–38.
Carlyle W, Killick L, Ancill R. ECT: an effective treatment in the screaming demented patient. J Am Geriatr Soc . 1991;39:637.
Roccaforte WH, Wengel SP, Burke WJ. ECT for screaming in dementia. Am J Geriatr Psychiatry . 2000;8:177.
Lau TE, Babani PK, McMurray LA. The treatment of disruptive vocalization in dementia (behavioral and psychological symptoms of dementia) with electroconvulsive therapy: a case series. J ECT . 2017;33:e9–e13.
Grant JE, Mohan SN. Treatment of agitation and aggression in four demented patients using ECT. J ECT . 2001;17:205–209.
Sutor B, Rasmussen KG. Electroconvulsive therapy for agitation in Alzheimer disease: a case series. J ECT . 2008;24:239–241.
Burton MC, Koeller SL, Brekke FM, et al. Use of electroconvulsive therapy in dementia-related agitation: a case series. J ECT . 2017;33:286–289.
Ujkaj M, Davidoff DA, Seiner SJ, et al. Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia. Am J Geriatr Psychiatry . 2012;20:61–72.
Isserles M, Daskalakis ZJ, Kumar S, et al. Clinical effectiveness and tolerability of electroconvulsive therapy in patients with neuropsychiatric symptoms of dementia. J Alzheimers Dis . 2017;57:45–51.
Hermida AP, Tang YL, Glass O, et al. Efficacy and safety of ECT for behavioral and psychological symptoms of dementia (BPSD): a retrospective chart review. Am J Geriatr Psychiatry . 2020;28:157–163.
Zhang QE, Sha S, Ungvari GS, et al. Demographic and clinical profile of patients with dementia receiving electroconvulsive therapy: a case-control study. J ECT . 2016;32:183–186.
Acharya D, Harper DG, Achtyes ED, et al. Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia. Int J Geriatr Psychiatry . 2015;30:265–273.
van den Berg JF, Kruithof HC, Kok RM, et al. Electroconvulsive therapy for agitation and aggression in dementia: a systematic review. Am J Geriatr Psychiatry . 2018;26:419–434.
de Medeiros K, Robert P, Gauthier S, et al. The Neuropsychiatric Inventory—Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr . 2010;22:984–994.
Rosen J, Burgio L, Kollar M, et al. The Pittsburgh Agitation Scale: a user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry . 1994;2:52–59.
Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry . 1988;23:271–284.
Ready RE, Ott BR, Grace J, et al. The Cornell-Brown scale for quality of life in dementia. Alzheimer Dis Assoc Disord . 2002;16:109–115.
Auer S, Reisberg B. The GDS/FAST staging system. Int Psychogeriatr . 1997;9(suppl 1):167–171.
Burke AD, Goldfarb D, Bollam P, et al. Diagnosing and treating depression in patients with Alzheimer's disease. Neurol Ther . 2019;8:325–350.
Olin JT, Schneider LS, Katz IR, et al. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry . 2002;10:125–128.
Lee HB, Lyketsos CG. Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry . 2003;54:353–362.
Sepehry AA, Lee PE, Hsiung GR, et al. The 2002 NIMH provisional diagnostic criteria for depression of Alzheimer's disease (PDC-dAD): gauging their validity over a decade later. J Alzheimers Dis . 2017;58:449–462.
Teng E, Ringman JM, Ross LK, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry . 2008;16:469–477.
Liu KY, Stringer AE, Reeves SJ, et al. The neurochemistry of agitation in Alzheimer's disease: a systematic review. Ageing Res Rev . 2018;43:99–107.
Chakraborty S, Lennon JC, Malkaram SA, et al. Serotonergic system, cognition, and BPSD in Alzheimer's disease. Neurosci Lett . 2019;704:36–44.
Abbas G, Mahmood W, Kabir N. Recent progress on the role of GABAergic neurotransmission in the pathogenesis of Alzheimer's disease. Rev Neurosci . 2016;27:449–455.
Calvo-Flores Guzman B, Vinnakota C, Govindpani K, et al. The GABAergic system as a therapeutic target for Alzheimer's disease. J Neurochem . 2018;146:649–669.
Pinna M, Manchia M, Oppo R, et al. Clinical and biological predictors of response to electroconvulsive therapy (ECT): a review. Neurosci Lett . 2018;669:32–42.
Baldinger P, Lotan A, Frey R, et al. Neurotransmitters and electroconvulsive therapy. J ECT . 2014;30:116–121.
Kato N. Neurophysiological mechanisms of electroconvulsive therapy for depression. Neurosci Res . 2009;64:3–11.
Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer's disease: what might be associated brain circuits? Mol Aspects Med . 2015;43-44:25–37.
Enneking V, Leehr EJ, Dannlowski U, et al. Brain structural effects of treatments for depression and biomarkers of response: a systematic review of neuroimaging studies. Psychol Med . 2020;50:187–209.
Helm K, Viol K, Weiger TM, et al. Neuronal connectivity in major depressive disorder: a systematic review. Neuropsychiatr Dis Treat . 2018;14:2715–2737.
Panisset M, Roudier M, Saxton J, et al. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol . 1994;51:41–45.
Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry . 2012;27:1248–1257.
Vigen CL, Mack WJ, Keefe RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry . 2011;168:831–839.
Kumar S, Mulsant BH, Liu AY, et al. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry . 2016;24:547–565.